Sharekhan's research report on Sanofi India
Sanofi reported weak performance for quarter and results missed estimates. Although numbers are not comparable on a y-o-y basis due to the hiving off of the neutraceuticals business. Revenues and adjusted PAT declined by 4.5% and 26.5% yoy respectively. Divesture of Nutraceuticals business as well as slow moving brands, to remove a drag on the company’s growth and would facilitate enhanced focus on key growth areas – anti diabetes, cardiac.. High-growth visibility from chronics, strong, debt-free balance sheet, sturdy dividends and healthy cash position are the key positives.
Outlook
We retain Buy recommendation on Sanofi India Limited (Sanofi) with a revised PT of RS 9250.
More Info
At 12:14 hrs Sanofi India was quoting at Rs 7,281.00, up Rs 3.55, or 0.05 percent.
It has touched an intraday high of Rs 7,369.00 and an intraday low of Rs 7,176.00.
It was trading with volumes of 1,490 shares, compared to its thirty day average of 861 shares, an increase of 73.08 percent.
In the previous trading session, the share closed up 1.98 percent or Rs 141.00 at Rs 7,277.45.
The share touched its 52-week high Rs 9,300.00 and 52-week low Rs 6,949.35 on 10 August, 2021 and 27 January, 2022, respectively.
Currently, it is trading 21.71 percent below its 52-week high and 4.77 percent above its 52-week low.
Market capitalisation stands at Rs 16,768.60 crore.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
Read More
